Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Amgen Inc. (NASDAQ:AMGN ... potential for AMGN lies in its innovative oncology portfolio, especially its BITE platform, which is expected to lead to several new treatments in the coming years.

We recently compiled a list of the 7 Cheap Quarterly Dividend Stocks to Invest in. In this article, we are going to take a ...

During his time at Amgen, Dr. McIver led the efforts in maximizing the value of bispecific T-cell engager (BiTE) assets across ... s product candidates and platform technologies, and expectations ...

During his time at Amgen, Dr. McIver led the efforts in maximizing the value of bispecific T-cell engager (BiTE) assets across multiple hematologic ... the potential benefits of Janux’s product ...

James Bradner; Executive Vice President - Research and Development; Amgen Inc Peter Griffith ... In oncology, our leading bispecific T-cell engager platform provides further opportunities for ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.